Dongkook Pharmaceutical Supports COVID-19 Testing Costs for Pediatric Cancer Patients
[Asia Economy Reporter Cho Hyun-ui] Dongkook Pharmaceutical announced on the 4th that it will support the COVID-19 testing fees for children with pediatric cancer and their guardians through the Korea Leukemia Children's Foundation.
Currently, most hospitals treating pediatric cancer require a negative COVID-19 test certificate for patient admission. Therefore, they decided to support the testing fees for pediatric cancer patients and their guardians who are frequently hospitalized.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051414165763158_1778735817.jpg)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- [Breaking] Park Sukeun, Central Labor Relations Commission Chair: "Some Gaps Narrowed Between Samsung Electronics Labor and Management"
- "If That's the Case, Why Not Just Buy Stocks?" ETFs in Name Only, Now 'Semiconductor-Heavy' and a Playground for Short-Term Traders
- "I Take Full Responsibility"... Chung Yongjin Issues Direct Apology for Starbucks 'May 18 Controversy' (Update)
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
A representative from Dongkook Pharmaceutical said, "We decided to support the testing fees to ease the financial burden on pediatric cancer patients and their families and to wish them a speedy recovery."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
